Q4 2021 US Physical Therapy Inc Earnings Call
[music].
Good day, everyone and welcome to the U S physical therapy fourth quarter and year end 2021 conference call. At this time all participants are in a listen only mode. Later, you will have an opportunity to ask questions. During the question answer session Me Ratcheted ask a question at any time a question to start and the number one on your Touchtone phone.
I will be say anybody should you need any assistance. Please note. This call maybe recorded it is now my pleasure to turn today's program over to Chris Reading C E O.
Thank you good morning, and thanks, everyone for joining us for U S physical therapy fourth quarter and year end 2021 earnings call.
Several of our team are on the road. This morning working on new opportunities include Eric Williams, Our Chief operating officer for the eastern half of the country with Vince <unk>, Our executive Vice President and General Counsel on the line, we have Gary Hendrickson with me here in Houston, Our Chief Financial Officer, Graham Reeve our CEO .
Oh for the western half of the company along with Jon Bates, Our Vice President controller before I provide some color on the year quarter need to cover a brief disclosure statement John If you would please thanks Chris.
This presentation contains forward looking statements, which involve certain risks and uncertainties. These forward looking statements are based on the company's current views and assumptions and the company's actual results can vary materially from those anticipated.
Please see the Companys filings with the Securities and Exchange Commission for more information. Thank you John .
So I want to start this morning.
And cover some highlights on the year.
For the year operating income increased $18 2 million or 34, 8% compared with 2020.
Reported revenue increased 17% to 495 million.
<unk> net revenue increased 17, 4%.
As Youre aware in 2021, we were hit with reduced Medicare pricing, which in turn impacted our net rate, which dropped slightly from $105 66, and 2021 O 388 in 2020 one.
Visits were very strong throughout most of the year up 19, 4%. Despite the fact that comparable numbers in the latter part of 'twenty 'twenty were also very strong boy.
Volumes for most of the year, beginning March and continuing through year's end were at record highs for us exceeding 29 visits per clinic per day for those 10 straight months.
Is it from mature clinics increased 17 eight.
<unk>, 8% for the year.
Management contract revenue was up 17, 2% on a year.
And our injury prevention services revenue increased 12% on a year to 38, 5% in the fourth quarter.
Total operating costs were impacted in 2020 , one by inflation, along with some labor escalation.
Part of that and in spite of the.
The net impact from Medicare we finished with total operating cost as a percent of revenue at 76, 3% versus 76, 7%, both 2020 and 2019.
Further our total operating cost per visit decreased slightly in comparison in 2021, and we finished the year at 79 point.
79.70 per visit and then 2019 again pre pandemic Lee we were at $81 38 per visit.
Our team has worked really hard all year to balance and control the cost equation, along with the growth in visits per clinic per day.
Done an excellent job.
Total salaries and related cost held up well for the majority of the year, Although we did experience some slight upward migration in the latter part of the year.
Despite that we finished 2021 with salary cost as a percent of revenue 56, 3% compared to a pre pandemic level in 2019.
56, 9%.
Salary and related cost performed well this year ending up.
Ending at 57 point to zero on a per visit basis for 2021 compared to 57.26 and 2020.
And as you know 2020 included a period of significantly reduced salaries early on in the pandemic and continuing actually through a good chunk of the year.
We also compared very favorably to where we were in 2019 at 59 to four.
Per visit that's a 350 basis point improvement from that pre pandemic here.
Gross profit was $117 two.
$2 million.
2021 an increase of 19, 1%.
Gross margin ended up 40 basis points better on a year or 23, 7%.
<unk> margins were up 70 basis points to 23, 8% while management contract margins were down slightly to just under 16%.
Our injury prevention business, which has been impacted by remote workers as well as Covid finished at 24, 4% down slightly from 25, 7% on what was a very tightly controlled expense here in 2020 with very little travel.
And no major conferences attended.
Our performance included the addition of our newly acquired industrial injury Prevention business late in the year. This business has a slightly lower margin profile compared with our legacy business and the combined margins will be reflective of that difference going forward.
Operating income for 2021 increased $18 2 million or 34, 8% from 2020 operating income margin improved 190 basis points to 14, 3%. Despite the many challenges we have faced throughout the past year, including Covid staffing inflation.
And all the rest.
In 2021, our company deployed significant acquisition related capital across several deals in the PC space two in the injury prevention area, including our largest to date, which we announced late in the fourth quarter of last year.
Terry is going to review a few of our total use of free cash flow and I think you'll find it pretty impressive on a year, what we were able to get done while still keeping our debt to EBITDA ratio in very good shape.
In response to the company's strong performance in 2021 and our continued confidence in our ability to grow our board of directors has voted to increase the first quarter dividend from 38 per share 41 cents per share, which is an increase of approximately 8%.
From the last dividend, but an increase of approximately 12, 3% when compared to our average dividend paid in 2020.
You may recall that midway through 2020 for the third and fourth quarters I'm, sorry for 2021 for.
For the third and fourth quarters, we increased our dividend.
As stated in our press release I'm immensely appreciative of the fine work and results produced by our partner led teams all year all of them along with our home office support group in Houston is not only function well and he is exceedingly difficult and rapidly changing times.
We have worked effectively under difficult circumstances to produce a record earnings year for the company.
Our services, which keep people on the job and healthy along with those who may have suffered a serious musculoskeletal injury. They help.
Make people's lives better more enjoyable more productive and ultimately.
With a documented improvement in our overall health and wellbeing. This allows people to stay in the workforce as well as to do productive and enjoyable things with and for their families at a time in our nation needs all of those things very much.
Speaking of the labor market I would like to address staffing from that.
Well I would characterize the current environment is challenging for finding staff and for the increased time that it takes to do that right now our turnover rate for licensed clinicians is actually down slightly as compared to where we ran on a pre pandemic basis in 2019.
Yes.
Kind of sit for a minute. So when you look at when you look at our turnover rate from most important group, which is our clinical group our license clinicians, it's actually down as a percentage compared to where we were in 2019.
We thought 2019.
As being a very normal operating and hiring environment now.
On our front desk unlicensed support staff, our turnover rate is definitely higher and we're working hard and making some continued adjustments to overcome that but I.
I will say that our partners along with our <unk>.
Vamp recruiting group I've worked their tails off all year to stay on top of this issue and to deliver good strong candidates were where we needed them as a result of some normal turnover, whereas the case has been through much of the year as a result of some very strong expansion and volume growth.
Which required the need for additional clinicians.
So while the environment is definitely challenging and in some cases, we are seeing an upward migration in terms of salaries overall I think we've done a pretty good job in this area as evidenced by our strong results for the year, both in terms of cost and also.
Our earnings growth.
So that concludes my prepared comments Kerry if you would please cover some of the additional aspects of our financial performance as well as our guidance before we open it up for questions.
You, Chris and good morning, everyone.
Are you pleased with the results our team achieved in 2021, we had significant growth in all of our key metrics many of which Chris noted in his remarks, our operating results. Excluding relief funds finished at $3 17 per share for the full year and at <unk> 72 per share for the fourth quarter, both of which were higher than the high end of our guidance that we provided.
And were higher than analyst consensus estimate as well not included in these numbers is another $4 $6 million in cares where lead times are received and recorded in the fourth quarter of 2021.
Our $3 17 of operating results, excluding relief tons or 32, 6% higher than the $2 39. Since we reported on the same basis for 2020, and there are $12, 4% higher than the $2 82.
We reported for the pre pandemic year of 2019.
Our fourth quarter 2021 operating results, excluding released on <unk> of 72 per share compares to 85 in the fourth quarter of 2020, which benefited from reduced expense levels due to the pandemic and a slight rate adjustment we had related to earlier 2020 periods and it's 12, 5% higher than the 64 <unk> we reported.
For the pre pandemic fourth quarter of 2019.
Our adjusted EBITDA, excluding relief funds was $74 $3 million for the full year of 2021, which was an increase of 31, 5% from full year 2020, and an increase of two 1% from pre pandemic 2019.
The same measurement with $17 million in the fourth quarter of 2021 compared to $18 $3 million in the fourth quarter of 2020, and it was 10, 9% higher than the $15 3 million of adjusted EBITDA reported for the fourth quarter of 2019.
Our full year 2021 revenues increased to $495.01 million, a 17% increase over full year 2020, and our fourth quarter 2021 revenues increased to $129 $8 million, which was a 10, 5% increase over the fourth quarter of 2020.
Our physical therapy patient visits per clinic per day continued at a record pace in the fourth quarter, finishing at $29 eight for the fourth quarter of 2021, the only quarter hiring in our company's history was the second quarter of 2021, when our average visits per day or 30.0 and for the full year, our average visits per clinic per day.
Finished at $29 one.
Prior to March of 2021, we'd never had a single month 29 average visits per clinic per day and this year. We finished for the full year above 2009, a real testament to our operating team.
Our net rate for our physical therapy operations was $103 88 for full year 2021, as compared to $105 66 for the full year of 2020, and our net rate was 103 53 in the fourth quarter of 2021 compared to $107 <unk> in the fourth quarter of 2020.
Our 2021 full year and fourth quarter rates reflect the three 5% Medicare rate cut that went into effect in January of 2021, as well as some shift in the mix of our business.
Right workers comp visits have not yet returned to pre pandemic levels, while Medicare visits which are paid at a lesser rate than overall average rate have increased above pre DAC pre pandemic levels.
Put some downward pressure on our overall rate in 2021.
So that net rate in the fourth quarter of 2020 was high it included the slight adjustment related to earlier 2020 periods that I mentioned earlier.
Our physical therapy revenues were $441 3 million for the full year of 2021, which was a 17, 6% increase over 2020, and they were $114 2 million for the fourth quarter of 2021, which was eight 6% higher than the fourth quarter of 2020.
In the industrial injury prevention business full year and fourth quarter of 2021 revenues were all time highs of $43 9 million and $13 $4 million, respectively that was a 12% increase over 2020, and a 38, 5% increase over the fourth quarter of 2020 as Chris noted in his remarks.
The fourth quarter of 2021 included the one month of operations related to the November 30 acquisition that we made are in the industrial injury prevention services business.
Our operating costs were well contained in 2021 as Chris noted in his remarks, and we are well aligned with our growth in revenue or cost per visit did increase from the third quarter to the fourth quarter of 2021 with most of the increase in salaries as we continued to build our staff to the levels needed to support our record volumes and also we had some higher contract services cost in the.
<unk> fourth quarter due to having a higher number of employees out due to COVID-19 .
Our gross profit was $117 2 million for the full year of 2021, which was a 24, 1% increase over full year 2020.
Our gross profit for the fourth quarter of 2021 was $27 $2 million compared to $29 1 million in the fourth quarter of 2020 and $27 million in the fourth quarter of 2019.
Our gross profit margin was 23, 7% for the full year of 'twenty one.
It was 22, 3% in full year, 2020 three 3% in full year 2019, so it was higher than both of those full year margins.
Our corporate office costs were $46 $5 million for the full year and $10 7 million for the fourth quarter.
If you exclude the incremental equity compensation expense that we had in 2021 related to the retirement of our COO for the West Division, our corporate office costs were nine 1% of revenues for the full year of 2021, which is lower than the nine 6% of revenues for the full year 2020 on the same basis and nine 3% of revenues for prepayment.
2019.
Our net income that was attributable to our Noncontrolling interest was $17 $1 million for the full year of 2021, which was 13, 9% of our profits. This compares to 16% for the full year of 2020.
Reduction in our Noncontrolling interest percentage is primarily due to our purchase of Noncontrolling interest from existing partners in 2021 and.
In 2021, we purchased $31 $1 million of Noncontrolling interest from our existing partners, representing EBITDA of approximately $4 1 million with $14 million of those purchases occurring in the fourth quarter of 2021.
The fourth quarter of 2021, Noncontrolling interest as a percent of our profits was 13, 3%, which compares to 16, 3% in the fourth quarter of 2020.
Our balance sheet remains in an excellent position and our cash generation remains strong we ended the year with $114 million on our revolving credit facility, including approximately $62 million added to the line on November 30 for the acquisition of the industrial injury prevention services business and about $3 $5 million for the acquisition of three clinics.
On December 31.
Our net debt at December 31, 2021 was $94 million, which includes the $114 million on our credit facility $4 2 million and deferred payroll taxes under cares and $4 4 million in notes payable net of $28 6 million in cash. So that's net debt in December 2020 on was 94.
<unk>.
Our net debt at December 31, 2020 was $11 million.
In 2021, we funded acquisitions totaling approximately $87 million.
We invested $8 2 million in fixed assets, we paid back $14 1 million and Matt funds, we paid back $4 1 million and deferred payroll taxes under cares.
We purchased Noncontrolling interest from our partners of $31 million.
Dividends of $18 $8 million and paid off $4 9 million in notes payable all of which total $168 $1 million, but our net debt position increased by only $83 million.
Our low leverage and our strong cash generation provide us with tremendous flexibility and sufficient capacity for the right growth opportunities as we identify them.
As we look to 2022, we're optimistic about our prospects for the year and our teams operating ability to successfully manage through the Medicare rate reductions for 2022.
We managed very successfully through the 2021 rate reduction and we're confident we'll do so again.
In our release, we provided a range of $3.
Five to $3 35, and operating results per share for 2022.
The range considers the following all of which we had previously announced a Medicare reduction for the full year of 2022 of approximately 0.75%.
The phase out of sequestration relief was which results in a 1% reduction in the rate applied to all Medicare payments for the second quarter of 2022, and a 2% reduction in the rate applied to all Medicare payments in the third and fourth quarters of 2022 and it also includes a 15% decrease in rate for care provided to Medicare patient physical.
Therapy assistant effective January one 2022 altogether. These Medicare rate reductions are expected to reduce our 2022 revenue by approximately $4 2 million, which amounts to 21 per share.
As a point of information Medicare visits represent approximately one third of our total patient visits.
As usual the range does not include any potential acquisitions, we may make in 2022.
The guidance range implies a 10% to 13% increase in our operating results per share before the Medicare rate reductions and a two 5% to five 5% increase in our operating results, including the Medicare rate reductions with that I'll turn it back to Chris Yes, good job Kerry. Thank you.
Operator, let's go ahead I'm sure you'll have questions. So let's go ahead and open up for questions.
At this time, if you'd like to ask a question. Please press star one on your Touchtone phone you may remove yourself from the queue at any time by press Makowski. Once again that is star one to ask a question and we'll take our first question from Larry Solow with CJS Securities. Good morning, Larry Good morning, Larry Good morning good.
Good morning, guys.
Quickly on the guidance.
I guess two questions on the guidance, maybe just some high level can you just give us a high level.
Sort of.
Same what you're sort of thinking about same store sales volumes and then.
In terms of margin just directionally, if you can give us any thoughts on that and then.
That question is sort of I know you don't guide quarterly, but how should we think of cadence I missed the comment to the call, but Q1, obviously there is especially early in the quarter.
Flurry of Covid, and we all know somebody if not ourselves without for five days.
Their brother had Wi Fi.
We had it so trying to figure out how that you're maybe employee situation in the first quarter might be worse than the rest of the year. So just any thoughts on cadence would be great.
Let me talk let me do the cadence part and then I'll kick it over to carry on the other so for the cadence I think you're exactly right for the first quarter.
Between Omicron Covid.
And the weather, which we always have in the first quarter first quarter is going to be the lighter quarter for the whole year no doubt I will tell you on a positive note. While we were heavily in January with Covid.
Youre right a lot of people very effective in <unk>.
Short of quarantines and shorter out periods.
As a result of the updated CDC guidance, but a lot of folks out.
Combined with weather, but the Covid thing has begun to dramatically improve.
Over the last couple of weeks, so we've seen a big drop off there.
Drop off being an improvement in.
And now we've just got to get through the rest of it we're getting some weather again this week, but we just got to get through the rest of the weather and then get to.
The war.
Yes, Larry is as far as as far as the <unk>.
<unk> clinics in the growth expected in 2022 went in inside the guidance has built in about a 2% to 3% increase in volume for our mature clinics and then the net rate with all things considered it's going to be down about 1% or a little bit little bit.
North of 1% so.
That's the pieces of that for mature clinics, and then from a margin standpoint, I think we should you should probably expect something like what we had in the fourth quarter going forward in 2022.
Okay in terms of pricing, obviously, we know the government pricing.
So it sounds like.
Medicare Medicare your ceiling private pay commercial pay is about flat right.
Yes.
Yes, yes, we've assumed that in the budget.
On on some very capable shoulders here, we've placed an enormous.
<unk> focus around contracting this year.
Then aside from just straight contracting with commercial payers.
It's something that I can't go into a great detail, yet, but we're about to kick off a program that we think will help to fill in some of the <unk>.
Some of the Dart.
We're losing as a result of the Medicare cut.
And so that's we're on the cusp of that as well.
So we're working on it and it'll be a focus all year for sure.
I would think maybe not in the immediate term, but over the mid term.
Was this kind of inflation right.
Costa Rica Paris.
You got some leverage.
There's always pushback, but I would think you have.
Average there against them on that right.
Yes.
Yeah, I don't know if it's the leverage but it's certainly rational response would would seem to be that.
Payers are going to have to understand that.
Everybody's cost has gone up and if rates don't go up so.
A problem.
Right and then just last question on the on the turnover. So it sounds like it's not really a clinician issue for you guys. It's more back office admin staff and stuff like that I guess right.
And I will say even with that.
I will tell you and Kerry can maybe speak to our revenue cycle group has done a great job for the year, just hats off to them and May have may have in some cases struggled to replace people quickly, but even with that I've got to tell you. Our people really stepped up this year not.
Not just this year, but the last couple of years in so many ways and so Carrie I don't I don't know if you have any.
Yes.
Despite all of the.
Number of employees, we had throughout the year. The team just worked incredibly hard to keep our I mean, our billing and collections well and in line with where they've been in previous years, certainly with pre pandemic 2019, and we were able to close a few of our central billing offices and move them into more profitable ones and that kind of things we made some headway this year.
We did a great job right.
I appreciate it guys. Thanks, so much.
Our next question comes from Steph Wissink with Jefferies.
Hey, Steph. Thank you for all of the information everybody I do have another follow up question just on the cadence I just want to make sure. We're hearing you correctly in terms of how you expect sequentially the business to kind of build back in as you think about the acquisitions that you completed last year kept plugging nothing to the productivity wheel.
Thinking about the organic nature of the contribution of growth from those kind of late late stage acquisitions in 'twenty one.
Yeah, well the ones we did late in the year, we'll certainly we'll have the benefit.
Through the entirety of this year.
So the cadence we had one in June .
We had one I think in March end of March we had small injury prevention deal in September the big injury prevention deal at the end of November and then a small deal right PT deal right at the end of the year. So all of those will we'll layer layer and accordingly.
Oh for sure for the first quarter, Mike mentioned on cadence had more to do with.
Just the environment.
Coming out of the gate in January between weather.
January the first week of February or so.
Covid and weather.
So therefore, I think we'll see some some.
Some forward waiting.
And not equal waiting through the quarters, which is really our typical cadence more than anything but you will see that again. This year Q1 is always lower for us.
Getting started out of the gates and because of weather issues in the kinds of things. We're having this year just like we normally do the second quarter typically in March or April is when volumes really began to pick up and that was the case last year for sure and continue from that point through the rest of the year than the second quarter is typically the second quarter and the fourth quarter are typically our higher quarters.
And then the third quarter.
Has a little bit of a lull because of summer and people being off in.
So and that's typically the pattern and I think that would hold into 2022 as well and the acquisitions. The largest one of course is the one that we did in November on November and I would expect that to perhaps start off a little bit slower in the first part of the year and grow as the year goes along is what I would expect from that one okay.
Great great.
Okay very helpful. And then just my follow up is on the waves of Covid that we've seen I'm, hoping you can kind of compare and contrast delta versus omicron. It sounds a little bit like Youre omicron impact was a bit more intense over a shorter period of time is that a fair assessment or how would you kind of help us think through.
Serving in your business in terms of recovery post wave.
Yes, so definitely fair assessment Omicron was.
So we think we had more people out with them on crime than we did even with delta, but that all the time was shorter.
And the drop off has been pretty precipitous since things have settled down and so.
Fingers crossed that there is not.
Not another Greek alphabet letter come waiting for us but.
Right now we're doing better.
Okay. We're with you on that last one for US is just an ability to recruit and retain any changes in the labor environment that you'd want to flag for us or considerations that you're thinking about your underlying de novo growth and then staffing up into some of the acquisitions that you've completed.
Yes, let me kick that over to Mike <unk>.
Eric and Graham their frontline and so I'll, let them comment.
Yes, Chris This is Eric yeah from a recruiting perspective.
You had mentioned earlier I mean, we're down about three percentage points from our our turnover rates pre tax pre pandemic in 2019.
And in terms of recruiting the additional investments that we made in our recruiting department, adding additional staff. There made a huge difference in terms of our ability to backfill open positions. The biggest challenge for US again, not clinically. It's just the turnover rates very competitive out there for front office and admin staff, but we're having success there as well.
But turnover rates still continue to be high.
Graham if you could speak to how that impacts our de novo and what the de Novo.
Brian It looks like for <unk> for both east and West for this year since we just finished the board meeting.
Graham you there Eric.
Eric do you want to speak to de Novo in staffing and overall pipeline.
Yes, so theres novel pipeline is really really strong, but we did see a delay we actually expected to open up more facilities in 2021, but as a result of again.
A competitive environment out there from staffing it slowed it down the bigger piece is really on the de Novo front, Chris was related to.
The ability to get contractors and permits on a timely basis that was absolutely an even bigger impact for us in staffing, but de novo pipeline very very strong here for 2022 as well.
Thank you okay.
Does that answer Okay, Hey, Doug.
Our next question comes from Matt Obrien with William Blair.
Okay.
Hi, This is madeline Goldman on for Matt.
I just want to touch on the industrial injury prevention segment, where you.
Just wondering when do you expect trades for that segment.
And sort of restart and have you now that Amazon is kind of declining have you started to have conversations around acquiring new clients for that segment.
And then as a follow up do you think that the current labor environment and the currently employed actually will lead to greater interest in industrial injury Prevention services do you think that's going to be a catalyst for growth there.
Yes, So let me unpack that so first trade shows while we haven't I don't think yet of attended many trade shows do I am hopeful I think the team is hopeful that those will come back sometime this year soon.
Sooner than later I think most everybody is very anxious to kind of get it back to Scott.
Normal directionally headed that way.
Our.
Ability, we're talking to new opportunities all the time, we're signing new opportunities.
As we go I think certainly the ability to get face to face will help that and accelerate that opportunity.
The impact that we felt in spite of that I think the team's done a wonderful job.
I'm trying to remember.
There was another.
Oh, the labor environment, the labor environment, the labor environment currently does impact our ability we sign a new opportunity and then we've got a we've got to find staff.
To do this so different in the clinics, where we may take.
One person or sometimes to people from an existing staff to go see a satellite opportunity, we don't always have that ability geographically too.
You know to pull from somewhere else.
So we have to find these people kind of from scratch they have to be recruited and on boarded.
A little bit longer than normal so that's been some of our impact, but I'm hopeful that as we go forward since we have been able to attract good clinicians that will also improve as the year unfolds.
Yes.
Great. Thank you and then just one quick question on M&A, given some of the unfavorable and reimbursement.
Do you think that's been pressuring providers have you seen an uptick in inbound related to M&A.
Yeah.
We're busy right now we have.
We have more scheduled calls than we've had in some time now I don't I'm always cautious.
People don't get too far ahead, because inbound calls don't always immediately translate to close deals but it's.
It's active I do think the environment look our partners that kind of <unk>.
Partnering with.
By and large I am talking about acquisitions, and not necessarily tuck ins, which are much smaller but.
Our partners are not afraid or potential partners. The people, we're talking to they're not afraid.
In many cases.
Seeing opportunities to do tuck ins and to move market share in their markets, but maybe they need some resources to do that capital resources or infrastructure resources and maybe they just wanted to take some chips off the table and <unk>.
The benefit from the additional resources to continue to grow but yes, I think any time there.
Storms.
Our lengthy and we've certainly been a series of lengthy storms I think that creates.
I think that causes people to look for a little bigger boat.
Got it out the next time and so I think it'll be helpful.
Great. Thank you.
Thank you.
And once again that is star one to ask a question. Our next question comes from Richard <unk> with Sidoti.
And Mitra.
Yes.
Yes.
Okay.
Okay.
Peter Your line is open.
I'll tell you what <unk> always good about asking questions why don't you.
Why don't you go to the next person and maybe we can come back to him in a minute is that possible.
There are no further questions.
Okay.
Alright, Beecher give us.
Give us a call.
<unk>.
Sorry for the technical difficulty I'm not sure but.
And I are available.
Following this corn through the rest of <unk>.
Today, we appreciate.
Your interest and your time everyone.
We thank you for the time. This morning. Thank my team for all the work that they've done as well.
Have a great day.
Thank you all this concludes today's program. Thank you for your participation you may disconnect at any time.
[music].
Okay.
[music].
Yes.
Yeah.
Okay.
Yeah.
Yes.
Yes.
Sure.
Okay.
Yes.
Okay.
[music].
Okay.
Yes.
Sure.
[music].
Okay.
Yes.
Alright.
Yes.
Okay.